UY26850A1 - Activadores de la benzeno acetamida glucoquinasa alfa-acil y alfa-heteroátomo sustituida. - Google Patents

Activadores de la benzeno acetamida glucoquinasa alfa-acil y alfa-heteroátomo sustituida.

Info

Publication number
UY26850A1
UY26850A1 UY26850A UY26850A UY26850A1 UY 26850 A1 UY26850 A1 UY 26850A1 UY 26850 A UY26850 A UY 26850A UY 26850 A UY26850 A UY 26850A UY 26850 A1 UY26850 A1 UY 26850A1
Authority
UY
Uruguay
Prior art keywords
alfa
activators
heteroátomo
glucoquinasa
acil
Prior art date
Application number
UY26850A
Other languages
English (en)
Inventor
Robert Francis Kester
Ramakanth Sarabu
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of UY26850A1 publication Critical patent/UY26850A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/46—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylureas
    • C07C275/48—Y being a hydrogen or a carbon atom
    • C07C275/50—Y being a hydrogen or an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C07C317/46—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D277/12—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/18—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C07D309/12—Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pyridine Compounds (AREA)

Abstract

Compuestos acetamidas bencénicas sustituidas que son activadores de la glucoquinasa y sus sales farmacéutimanete aceptables.
UY26850A 2000-07-20 2001-07-19 Activadores de la benzeno acetamida glucoquinasa alfa-acil y alfa-heteroátomo sustituida. UY26850A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US21987200P 2000-07-20 2000-07-20

Publications (1)

Publication Number Publication Date
UY26850A1 true UY26850A1 (es) 2002-01-31

Family

ID=22821104

Family Applications (1)

Application Number Title Priority Date Filing Date
UY26850A UY26850A1 (es) 2000-07-20 2001-07-19 Activadores de la benzeno acetamida glucoquinasa alfa-acil y alfa-heteroátomo sustituida.

Country Status (21)

Country Link
US (2) US6486184B2 (es)
EP (1) EP1305301B1 (es)
JP (1) JP4138478B2 (es)
KR (1) KR100556323B1 (es)
CN (1) CN1184214C (es)
AR (1) AR032626A1 (es)
AT (1) ATE297907T1 (es)
AU (2) AU8760001A (es)
BR (1) BR0112658A (es)
CA (1) CA2416229C (es)
DE (1) DE60111534T2 (es)
DK (1) DK1305301T3 (es)
ES (1) ES2243547T3 (es)
GT (1) GT200100146A (es)
MX (1) MXPA03000365A (es)
PA (1) PA8522701A1 (es)
PE (1) PE20020335A1 (es)
PT (1) PT1305301E (es)
UY (1) UY26850A1 (es)
WO (1) WO2002008209A1 (es)
ZA (1) ZA200300173B (es)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0102299D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
EP1336607A1 (en) * 2002-02-19 2003-08-20 Novo Nordisk A/S Amide derivatives as glucokinase activators
PL370989A1 (en) 2001-12-21 2005-06-13 Novo Nordisk A/S Amide derivatives as gk activators
PT1501815E (pt) * 2002-04-26 2007-01-31 Hoffmann La Roche Fenilacetamidas substituídas e a sua utilização como activadores de glicocinase
RU2340605C2 (ru) 2002-06-27 2008-12-10 Ново Нордиск А/С Арилкарбонильные производные в качестве терапевтических средств
PL215132B1 (pl) 2002-06-27 2013-10-31 Novo Nordisk As Pochodna arylokarbonylowa jako srodek terapeutyczny, jej zastosowanie i kompozycja farmaceutyczna ja zawierajaca
BR0314864A (pt) * 2002-10-03 2005-08-02 Novartis Ag Compostos orgânicos
GB0226931D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
MY141521A (en) 2002-12-12 2010-05-14 Hoffmann La Roche 5-substituted-six-membered heteroaromatic glucokinase activators
WO2004063194A1 (en) * 2003-01-06 2004-07-29 Eli Lilly And Company Heteroaryl compounds
PL378117A1 (pl) * 2003-02-11 2006-03-06 Prosidion Limited Tricyklopodstawione związki amidowe
RU2381233C2 (ru) 2003-09-30 2010-02-10 Ново Нордиск А/С Агонисты рецептора меланокортина
EP2298337B1 (en) 2003-12-09 2017-02-22 Novo Nordisk A/S Regulation of food preference using GLP-1 agonists
KR101126225B1 (ko) 2004-01-06 2012-04-12 노보 노르디스크 에이/에스 헤테로아릴-유리아 및 글루코키나아제 활성제로서의 그들의 사용
WO2005095417A1 (en) 2004-04-02 2005-10-13 Novartis Ag Thiazolopyridine derivates, pharmaceutical conditions containing them and methods of treating glucokinase mediated conditions
CN1960995B (zh) 2004-04-02 2010-12-08 诺瓦提斯公司 作为葡糖激酶活化剂、可用于治疗ⅱ型糖尿病的磺酰胺-噻唑并吡啶衍生物
MXPA06012008A (es) * 2004-04-21 2007-01-25 Prosidion Ltd Compuestos de amida tri(ciclo) sustituidos.
WO2005120492A1 (en) 2004-06-11 2005-12-22 Novo Nordisk A/S Counteracting drug-induced obesity using glp-1 agonists
GB0418046D0 (en) * 2004-08-12 2004-09-15 Prosidion Ltd Eantioselective process
JP2008509898A (ja) * 2004-08-12 2008-04-03 プロシディオン・リミテッド 置換されたフェニルアセトアミドおよびグルコキナーゼ活性化剤としてのこれらの使用
KR20080024211A (ko) * 2005-07-08 2008-03-17 노보 노르디스크 에이/에스 디시클로알킬 우레아 글루코키나제 활성제
ATE547396T1 (de) 2005-07-08 2012-03-15 Novo Nordisk As Dicycloalkylcarbamoyl-harnstoffe als glucokinase- aktivatoren
US7884210B2 (en) * 2005-07-14 2011-02-08 Novo Nordisk A/S Ureido-thiazole glucokinase activators
ES2426345T3 (es) 2005-07-20 2013-10-22 Eli Lilly And Company Compuesto unidos en posición 1-amino
BRPI0615236A2 (pt) 2005-08-31 2011-05-10 Astellas Pharma Inc derivado de tiazol
JP2007063225A (ja) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
JP2009509988A (ja) 2005-09-29 2009-03-12 サノフィ−アベンティス フェニル−及びピリジニル−１，２，４−オキサジアゾロン誘導体、その製造方法、及び医薬品としてのその使用
GT200600429A (es) 2005-09-30 2007-04-30 Compuestos organicos
GT200600428A (es) 2005-09-30 2007-05-21 Compuestos organicos
JP2009514835A (ja) * 2005-11-03 2009-04-09 プロシディオン・リミテッド トリシクロ置換型アミド
ES2393757T3 (es) 2005-11-17 2012-12-27 Eli Lilly & Company Antagonistas de receptor de glucagón, preparación y usos terapéuticos
WO2007061923A2 (en) * 2005-11-18 2007-05-31 Takeda San Diego, Inc. Glucokinase activators
US8034822B2 (en) 2006-03-08 2011-10-11 Takeda San Diego, Inc. Glucokinase activators
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
WO2007143434A2 (en) 2006-05-31 2007-12-13 Takeda San Diego, Inc. Indazole and isoindole derivatives as glucokinase activating agents
US7910747B2 (en) 2006-07-06 2011-03-22 Bristol-Myers Squibb Company Phosphonate and phosphinate pyrazolylamide glucokinase activators
US7888504B2 (en) 2006-07-06 2011-02-15 Bristol-Myers Squibb Company Glucokinase activators and methods of using same
EP2086951B1 (en) 2006-11-15 2011-12-21 High Point Pharmaceuticals, LLC Novel 2-(2-hydroxyphenyl) benzothiadiazines useful for treating obesity and diabetes
US7902248B2 (en) 2006-12-14 2011-03-08 Hoffmann-La Roche Inc. Oxime glucokinase activators
US8163779B2 (en) 2006-12-20 2012-04-24 Takeda San Diego, Inc. Glucokinase activators
TW200831081A (en) * 2006-12-25 2008-08-01 Kyorin Seiyaku Kk Glucokinase activator
WO2008084043A1 (en) 2007-01-09 2008-07-17 Novo Nordisk A/S Urea glucokinase activators
JP5226008B2 (ja) 2007-01-11 2013-07-03 ノボ・ノルデイスク・エー／エス ウレアグルコキナーゼアクチベーター
JP5491871B2 (ja) * 2007-02-28 2014-05-14 アドビナス セラピュティックス プライベート リミテッド グルコキナーゼ活性化因子としての２，２，２−三置換アセトアミド誘導体、その方法及び薬学的応用
US8034819B2 (en) * 2007-03-07 2011-10-11 Kyorin Pharmaceutical Co., Ltd. Glucokinase activator
US8173645B2 (en) 2007-03-21 2012-05-08 Takeda San Diego, Inc. Glucokinase activators
EP2195304B1 (en) * 2007-10-08 2014-01-08 Advinus Therapeutics Private Limited Acetamide derivatives as glucokinase activators, their process and medicinal applications
US9340506B2 (en) 2007-10-08 2016-05-17 Advinus Therapeutics Limited Acetamide derivatives as glucokinase activators, their process and medicinal applications
CL2009000004A1 (es) * 2008-01-15 2010-02-19 Lilly Co Eli Forma cristalina de r-2-(4-ciclopropansulfonil-fenil)-n-pirazin-2-il-3-(tetrahidropiran-4-il)-propionamida; composicion farmaceutica que comprende a dicha forma cristalina; y uso para el tratamiento de diabetes o hiperglicemia.
RU2010134411A (ru) 2008-01-18 2012-02-27 Астеллас Фарма Инк. (Jp) Фенилацетамидное производное
EP2275414B1 (en) 2008-04-28 2015-06-10 Kyorin Pharmaceutical Co., Ltd. Cyclopentylacrylamide derivative
WO2009140624A2 (en) 2008-05-16 2009-11-19 Takeda San Diego, Inc. Glucokinase activators
US8450494B2 (en) 2009-06-22 2013-05-28 Cadila Healthcare Limited Disubstituted benzamide derivatives as glucokinase (GK) activators
KR20120047960A (ko) 2009-07-31 2012-05-14 카딜라 핼쓰캐어 리미티드 글루코키나아제(ｇｋ) 활성화제로서 치환된 벤즈아미드 유도체
WO2011080755A1 (en) 2009-12-29 2011-07-07 Advinus Therapeutics Private Limited Fused nitrogen heterocyclic compounds, process of preparation and uses thereof
WO2011095997A1 (en) 2010-02-08 2011-08-11 Advinus Therapeutics Private Limited Benzamide compounds as glucokinase activators and their pharmaceutical application
BR112012021231A2 (pt) 2010-02-26 2015-09-08 Basf Plant Science Co Gmbh método para acentuar o rendimento em plantas, planta, construto, uso de um construto, método para a produção de uma planta transgênica, partes coletáveis de uma planta, produtos derivados de uma planta, uso de um ácido nucleíco e método para a produção de um produto
EP2539364A1 (en) 2010-02-26 2013-01-02 Novo Nordisk A/S Peptides for treatment of obesity
WO2011117415A1 (en) 2010-03-26 2011-09-29 Novo Nordisk A/S Novel glucagon analogues
CN102959076B (zh) 2010-03-31 2015-09-16 斯克里普斯研究所 重编程细胞
EP2402327B1 (en) 2010-06-29 2018-03-07 Impetis Biosciences Ltd. Acetamide compounds as glucokinase activators, their process and medicinal applications
US20140031278A1 (en) 2011-03-28 2014-01-30 Novo Nordisk A/S Novel Glucagon Analogues
AR088161A1 (es) 2011-09-23 2014-05-14 Novo Nordisk As Analogos de glucagon
JP6594856B2 (ja) 2013-04-18 2019-10-23 ノヴォ ノルディスク アー／エス 医療用の安定な遷延性ｇｌｐ−１／グルカゴン受容体コアゴニスト
EP3151852A1 (en) 2014-06-04 2017-04-12 Novo Nordisk A/S Glp-1/glucagon receptor co-agonists for medical use
US20200223889A1 (en) 2017-03-15 2020-07-16 Novo Nordisk A/S Bicyclic Compounds Capable of Binding to Melanocortin 4 Receptor
US20210221867A1 (en) 2018-05-15 2021-07-22 Novo Nordisk A/S Compounds Capable of Binding to Melanocortin 4 Receptor
CA3093025A1 (en) 2018-06-12 2019-12-19 Vtv Therapeutics Llc Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs
WO2020053414A1 (en) 2018-09-14 2020-03-19 Novo Nordisk A/S Bicyclic compounds capable of acting as melanocortin 4 receptor agonists

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3776917A (en) * 1972-06-05 1973-12-04 Schering Corp 2-amino-6-phenalkyl-aminopyridines and derivatives thereof
JPS5564592A (en) * 1978-11-10 1980-05-15 Teijin Ltd Thiazolo 3, 2-a pyrimidine derivative, its preparation, and drug comprising it
JPS62153273A (ja) * 1985-12-26 1987-07-08 Tokuyama Soda Co Ltd ピラゾ−ル化合物
DK1169312T3 (da) * 1999-03-29 2005-01-31 Hoffmann La Roche Glucokinaseaktivatorer

Also Published As

Publication number Publication date
AU8760001A (en) 2002-02-05
ES2243547T3 (es) 2005-12-01
AU2001287600B2 (en) 2006-07-13
JP2004504388A (ja) 2004-02-12
US6486184B2 (en) 2002-11-26
DE60111534T2 (de) 2006-05-11
PE20020335A1 (es) 2002-04-30
US20020042512A1 (en) 2002-04-11
ATE297907T1 (de) 2005-07-15
EP1305301A1 (en) 2003-05-02
PA8522701A1 (es) 2002-10-24
JP4138478B2 (ja) 2008-08-27
KR100556323B1 (ko) 2006-03-03
CA2416229C (en) 2007-09-18
GT200100146A (es) 2002-07-04
DK1305301T3 (da) 2005-10-17
MXPA03000365A (es) 2003-05-27
US20020198200A1 (en) 2002-12-26
DE60111534D1 (de) 2005-07-21
CN1443177A (zh) 2003-09-17
WO2002008209A1 (en) 2002-01-31
US6608218B2 (en) 2003-08-19
CA2416229A1 (en) 2002-01-31
PT1305301E (pt) 2005-09-30
BR0112658A (pt) 2003-06-24
CN1184214C (zh) 2005-01-12
EP1305301B1 (en) 2005-06-15
AR032626A1 (es) 2003-11-19
ZA200300173B (en) 2004-04-07
KR20030016419A (ko) 2003-02-26

Similar Documents

Publication Publication Date Title
UY26850A1 (es) Activadores de la benzeno acetamida glucoquinasa alfa-acil y alfa-heteroátomo sustituida.
DE69925133D1 (de) Pyrrolobenzodiazepine
ES2170252T3 (es) Tetrahidroimidazopiridoindoldionas como inhibidores de cgmp especifico pde.
CY1108610T1 (el) Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
DK1280801T3 (da) Hydantoinholdige glucokinaseaktivatorer
AR027938A1 (es) Compuestos uracilo y utilizacion de los mismos
UY26380A1 (es) Inhibidores de fab i
RS49795B (sr) Sredstva sa antidepresivnim dejstvom
DK1282611T3 (da) Substituerede phenylacetatamider og anvendelse deraf som glucokinaseaktivatorer
ES2184149T3 (es) Paclitaxeles 6-tio sustituidos.
AR023777A1 (es) Nuevos compuestos
ECSP045245A (es) N-aril-2-oxazolidinona-5-carboxamidas y sus derivados
DE60135919D1 (de) Farnesyl transferase-hemmende 6-heterocyclylmethyl-chinolin und chinazol-derivate
ATE402149T1 (de) Heterozyklische substituierte amide, deren herstellung und anwendung
MXPA03003774A (es) Derivados de acilo y sulfonilo de 2-(trans-1, 4-diaminociclohexil)-purinas 6,9-disubstituidas y sus uso como agentes antiproliferativos.
SE9601556D0 (sv) New pharmaceutical formulation of a thrombin inhibitor for parenteral use
ES2190486T3 (es) 3-acetidinilalquilpiperidinas o -pirrolidinas como antagonistas de la taquicinina.
AR020563A1 (es) Compuestos (poli)tia-alquinoicos y sus derivados, composiciones que los incluyen y su utilizacion
SE9801494D0 (sv) Novel use
PT1044064E (pt) Dispositivo para o revestimento de granulos destinados a serem absorvidos por via oral
AR025796A1 (es) Quinazolinonas
ECSP034532A (es) Derivados del 1-aminobutan-3-ol sustituido
DE69936052D1 (de) N1 modifizierte glycopeptide
UY26329A1 (es) Antagonistas de los receptores de vitronectina
BR0016941A (pt) Derivados de aminometil-fenil-ciclohexanona

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20140917